Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 67
7 Summary of Workshop Topics To bring the workshop to a close, each session chair provided a brief synopsis of his or her session, reflecting on recurring themes and thoughts for the future. 1 CURRENT ANIMAL MODELS There is much that can be done in animal models that cannot be done in nonanimal models and humans, and there are regulatory requirements for testing in animals before investigational compounds can be tested in humans. Studies in animals allow, for example, evaluation of drug tar- gets, testing of pharmacokinetics, metabolism, distribution of investiga- tional compounds, and prediction of the dose that will be maximally efficacious and yet still tolerable and safe. Animal studies expand the understanding of the nervous system diseases and disorders in a defined system and allow researchers to draw links to clinical pathways and for- mulate hypotheses for human testing, In summary, said session chair Stevin Zorn, although we can learn much from animal models, it was emphasized in the presentations and discussion that what we learn depends heavily what questions are asked, 1 The topics highlighted in this chapter are based on the summary remarks made by each session chair during the final workshop session and at the end of his or her session. Additional comments by participants related to the closing remarks are also included. As noted in Chapter 1, comments included here should not be construed as reflecting any group consensus or endorsement by the Institute of Medicine or the Forum on Neurosci- ence and Nervous System Disorders. 67
OCR for page 68
68 ANIMAL MODELS FOR NERVOUS SYSTEM DISORDERS how those questions are asked, and how the results are interpreted. When failures in translation occur, some potential questions to ask are: was it the animal model itself, the analysis, the clinical trial, or another factor? In this regard, the importance of training in skillful study design and ap- propriate statistical analysis was discussed. Humans are uniquely different from animals in many ways and there really is no such thing as an animal model of human disease (e.g., an “an- imal model of depression”). It is important to recognize that animal mod- els are only models of what is being modeled. In other words, these animals are modeling specific perturbations in an effort to understand the biology and assess potential therapies. Bringing a new drug to market has numerous challenges and signifi- cant costs and many potential therapies fail to meet expectations in Phase III clinical trials. Solving the problem of attrition of investigational new drugs will require a “renaissance,” Zorn suggested. Preclinical and clini- cal scientists need to reunite and redefine what is needed to enhance translation from preclinical models to human clinical trials. Precompeti- tive alliances and cross-sector collaborations were mentioned as potential approaches. An issue that was raised by multiple participants was that effective, cross-discipline discussion will require a better understanding of each other’s vocabulary. Also discussed was the need for better definition of the behaviors and physiological measures examined in both the animal model and the hu- man condition. Clearly defining what is measured is important in terms of gauging reproducibility and validity of model systems. There was much discussion about the importance of measuring “the right thing,” but exactly what that is for a given model or disease was, and will continue to be, passionately debated. Another factor impacting the use of animal models is publication bi- as, including the tendency in the literature to publish more positive than negative findings; the publication of poorly designed, executed, or ana- lyzed studies that could contribute to uninformative conclusions; and cul- tural assumptions about what constitutes “good science.” To foster discussion it was suggested that perhaps it is time to design a whole new set of animal models based on emerging knowledge (e.g., from imaging and genetics), rather than trying to refine existing models. It was also suggested that much can now be learned from sophisticated, non-invasive studies in the living human brain that can inform develop- ment of animal models.
OCR for page 69
SUMMARY OF WORKSHOP TOPICS 69 BOX 7-1 Potential Methods for Increasing Translation • Development of hypothesis-driven experiments • Sample size calculations • Blind coding of analyses • Randomization of treatment assignments • Blinding of experimenter to treatment assignments • Careful matching of control and experimental groups (e.g., sex, age, strain) • Rigorous statistical approaches • Reproduction in independent cohorts • Multiple outcome measures • Matching basic and clinical endpoints • Regular testing for genetic drift or loss of phenotype • Use of sensitive positive controls • Control of testing parameters (e.g., time of testing, lighting conditions) • Automated testing • Low-stress, non-aversive testing environments NOTE: This list was identified and summarized by the rapporteurs. This list is not comprehensive and should not be construed as reflect- ing any group consensus. DISORDER-FOCUSED BREAKOUT DISCUSSIONS To foster more in-depth analysis of the translational success of animal models, the second session of the workshop featured concurrent breakout discussions on six areas of neuroscience research: neurodegeneration, Alzheimer’s disease, stroke, schizophrenia, addiction, and pain. Based on the breakout summaries provided by each group moderator when the full workshop reconvened (see Chapter 3), session co-chair Richard Hodes offered his perspective on the common themes and differences across the groups. Variable State of Understanding of Pathophysiology The understanding of underlying pathophysiologic processes is quite different for various nervous system disorders examined, Hodes said.
OCR for page 70
70 ANIMAL MODELS FOR NERVOUS SYSTEM DISORDERS Our understanding of the genetic component of Alzheimer’s disease, for example, has generated therapeutic targets that have been reproduced in animal models of particular disease features. This knowledge is both a strength and a weakness, Hodes cautioned. While there are potential tar- gets to capitalize on, it is important to remember, as Zorn noted above, that the full disease has not been modeled, only the target of interest. This is in contrast to other conditions such as schizophrenia, where there was discussion about the usefulness of current models and defining ex- actly what should be modeled. Therefore, the next steps for improving translation of animal models may differ depending on the current state of knowledge about the basic biology of diseases and disorders. Adequacy of Models Hodes recalled the summary from the stroke breakout group, where it was noted that adequate animal models of stroke exist, but translation of the science from animal model to humans has failed. It was suggested that this discordance between animal and human studies in stroke could be due to bias in both animal and clinical study design or to the failure of animal models to adequately mimic clinical disease. This was character- istic of much of the discussion in that there are a variety of possibilities to explain where the faults may be when models do not successfully translate. Hodes cautioned against letting the animal model become the “standard” and lamenting that the clinical state is not cooperating with the model. Risk That Research Is Constrained by Models As alluded to above, when models are considered adequate (e.g., ar- terial occlusion models of stroke) or compelling (e.g., transgenic mouse models of Alzheimer’s disease pathology), there is a risk that research then becomes restricted to those areas or models. In the case of Alz- heimer’s research, for example, the amyloid hypothesis has dominated. Only very recently has there been more interest in tauopathy and in mouse models that recapitulate tau-dependent neurodegeneration. It is important to keep an open mind when working with established models, and not become locked into them in a counterproductive way.
OCR for page 71
SUMMARY OF WORKSHOP TOPICS 71 Public–Private Cooperation Hodes observed that the discussion of the strengths and weaknesses of collaborative efforts tended to group cooperation into two types: paral- lel partnerships and cooperative relationships that involve sequential roles. Some discussions, for example, focused on concerns that academic institutions and not-for-profit organizations carry out the basic research, and then hand it off to drug discovery and development, as if these are two discrete components in the process and not one continuous pathway. STANDARDIZATION Issues surrounding the standardization of animal models were dis- cussed from the perspective of preclinical models of anxiety, cognitive assays, and Alzheimer’s disease models. Session chair Walter Koroshetz pointed out an overarching concern for these and all models is that the process of tool development and standardization of models is not easily funded or staffed. Koroshetz observed that inter-laboratory standardization may be more difficult for some tests than others. It is important to know what the different performance characteristics are for a particular test. For one of the studies, even with great efforts to standardize all parameters among test sites, there was inter-site variability in the results of one type of be- havioral assessment (elevated plus maze), but consistency among test sites with another (voluntary alcohol consumption). Another topic of discussion was concern about over-standardization artificially inflating significance and reducing generalizability. This was shown in a study in which heterogeneity was introduced systematically in the comparison of two strains of mice (by altering housing cage size, and lighting during testing). Under highly standardized conditions, the mag- nitude of the difference among strains was variable across the experi- ments. However, when select parameters were heterogeneous, there was remarkable consistency in the strain differences. There was also discus- sion about the use of primarily one or two particular inbred isogenic mouse strains for behavioral studies and whether that raises questions about generalizability beyond the model. In discussing better ways in which to assess animal behavior, it was noted that there can be tremendous interference introduced by the exper- imenter. One approach is to “take the experimenter out of the experi-
OCR for page 72
72 ANIMAL MODELS FOR NERVOUS SYSTEM DISORDERS ment,” automating as much as possible to minimize experimenter contact with the animal and to reduce variability. The use of visual touchscreens for cognitive testing of both mice and humans was described as an ex- ample of standardization, and translation of testing methods. The discussion also expanded on the point made in the prior two ses- sions that animal models do not simulate every aspect of a complex dis- ease, but they are very useful for dissecting out particular pieces. This applies not only to molecular pathology, but also to underlying perturba- tions to networks and functional circuits. Koroshetz reiterated a list of best practices for preclinical animal studies offered by Mucke, which included blind coding of all analyses and allocations, carefully matching experimental and control groups, rig- orous statistical approaches, reproducing results in independent cohorts at different times and in different conditions, using multiple outcome measures, quality control of animal models, validating across models and in the human condition, and including sensitive positive controls to help eliminate false negatives. Several participants noted that a positive con- trol need not necessarily be a compound, but rather, some demonstration that the assay is as sensitive as expected to pharmacological manipulations. Overall, there was spirited discussion about the value of standardiza- tion, with concerns raised that premature standardization might not be helpful and can stifle innovation. It was suggested that improving exper- imental procedures may be the most helpful to the field going forward. Many participants stressed the importance of best practices, training sci- entists in well-established principles of experimental design and analysis (e.g., statistical power), and bringing researchers together to share and compare approaches. CORRESPONDING ANIMAL AND CLINICAL ENDPOINTS Session chair Sharon Rosenzweig-Lipson observed that even though there may be corresponding preclinical and clinical endpoints for an as- pect of disease, scientists may not know whether that aspect predicts the whole disease or disease reversal. In other words, during discussions of corresponding endpoints, researchers take a step forward in translation, but not necessarily in prediction of therapeutic efficacy. It is important to establish what the corresponding endpoint is intended to predict. In this session, panelists discussed the role of corresponding end- points, the choice of endpoints, and bidirectional translation for the study
OCR for page 73
SUMMARY OF WORKSHOP TOPICS 73 of nervous system disorders. Prepulse inhibition was offered as an exam- ple of the ability to study the same endpoint in an animal model and in human testing. Relatively similar manipulations alter the phenotype in a corresponding manner in both animals and humans. The prepulse inhibi- tion assay has predictive validity for testing the activity of antipsychotics and for developing typical and atypical antipsychotics. Such a corre- sponding endpoint is valuable in the development of therapies for specif- ic symptoms, in this case therapies acting at specific nodal points within the complex circuitry of schizophrenia. The experimental autoimmune encephalomyelitis (EAE) model was described as an example of both success and failure within the same drug development program. The model predicted the efficacy of a humanized monoclonal antibody for the treatment of multiple sclerosis but failed to predict a serious adverse event. In a second example, differences in the way the EAE model was used by two different laboratories resulted in completely opposite results regarding the role of tumor necrosis factor (TNF) in multiple sclerosis. Clinical trials were conducted based on the animal study showing control of EAE by inhibition of TNF, but the trial results soon confirmed the animal study showing exacerbation of disease when TNF is blocked. Another example described how neuroimaging tools have allowed us to understand and exploit the fact that the functional components of hip- pocampal circuits are very similar in their core functions across animal models and humans. Every time we use an animal model to make a prediction, Rosenzweig-Lipson said, we need to know the level of understanding of the underlying pathophysiology on which the model is based, the validity of the model, and the level of risk in using the model to make a predic- tion. For some of the cognition models, for example, there is no “gold standard” model and the risk in making predictions using such a model may be very high. The risk may be lower for models based on a stronger understanding. The key questions are how big is the risk and how good is the prediction. Rosenzweig-Lipson suggested that there should to be honesty in dialogues about predictive value so that later, when there is a failure, it is understood that there was, for example, only a 20 percent certainty that the model was going to make a good prediction. In some cases it is not the models that need to be improved, she said, but the dia- logue about the models. One participant noted that the use of multiple models and reduction of relying on a single model might reduce risk through a layered strategy.
OCR for page 74
74 ANIMAL MODELS FOR NERVOUS SYSTEM DISORDERS THE BASIC AND CLINICAL SCIENCE GAP Several examples of efforts to bridge the translation gap between preclinical models and clinical trials were discussed, including National Institute of Mental Health–funded consensus-building initiatives (MATRICS and CNTRICS); a for-profit consultancy stepping into the gap between academia and industry to bring validated models to drug developers (P1vital); a company using quantitative systems pharmacolo- gy as a translation tool, applying mathematical model-based decision support to drug development (In Silico Biosciences); and a European Un- ion government–facilitated, precompetitive public–private partnership to address specific issues in drug development (NEWMEDS). Session chair Mark Geyer highlighted several take-away messages from the session. He continued on the theme that discussions about ani- mal models should focus on what is being predicted. This means not at- tempting to predict Phase III clinical trials outcomes, but more toward predicting Phase IIA results. As has been done in CNTRICS, Geyer suggested it is important to take the following steps: • Be clear about what is being measured. • Determine how to measure it in a human, both in healthy and af- fected individuals. • Design tasks that are simple, manageable clinical tools for exper- imental medicine. • Design tasks that are also nonverbal and amenable to study in animals. The structure of NEWMEDS and other IMI initiatives in the Europe- an Union are enabling researchers to interact both laterally (across insti- tutions and companies) to share data and ideas and vertically (from preclinical through to clinical). Geyer suggested that the United States can learn from this and improve upon it. CLOSING REMARKS Following the session summaries, workshop co-chair Hodes called for final comments and suggestions from participants for going forward.
OCR for page 75
SUMMARY OF WORKSHOP TOPICS 75 Participants continued to explore the impact of the terminology used to describe models, and offered suggestions for further discussion. Model Nomenclature as a Confounder Despite the broad recognition by many participants that animal mod- els need to be recognized as models of only an aspect of a disease and do not represent an entire disease pathophysiology and phenotype, it was acknowledged that most models are generally referred to as an animal model of a particular disease (e.g., “an animal model of schizophrenia”). Expanding on the discussion in session IV (Chapter 5), it was suggested that equating an animal model of a particular phenotype to a human dis- ease, and discussing the results of a study as a “treatment” or “cure” for the phenotype or disease, can be very misleading. The animal, in fact, never had the full human disease and was not cured. It was also sug- gested that researchers are misleading each other with these “therapeutic misconceptions.” In this context, it was suggested that authors of manu- scripts, reviewers, and journal editors should carefully examine the weight assigned to published results. It was reiterated that clinical trials are conducted for a particular dis- ease and geared toward a drug label indication for treating specific symp- toms in the context of the disease. Some participants, however, suggested engaging regulators and others in discussions on this topic during early stages of development, qualification, and validation of biomarkers and endpoints. One can back-translate from the disease to the animal model, but that does not mean it is an animal model of the disease. In depression, for example, one model used shows an effect on emotional processing, which is a prelude to mood change. This rat model is not about mood; it is about how the animal evaluates rewards and how researchers evaluate emotional stimuli. SUMMARY The use of animal models has led to a better understanding of nerv- ous system disorders and diseases and the development of new therapeu- tics. However, given that there are still few treatment options for many diseases, this workshop sought to concentrate on several important ques- tions: What leads to poor translation of animal models to clinical prac-
OCR for page 76
76 ANIMAL MODELS FOR NERVOUS SYSTEM DISORDERS tice? Is it the models themselves, research expectations, how models are used to make predictions and decisions, or perhaps the level of knowledge about underlying pathophysiology for any given disease? At each step of the therapeutic development pathway, speakers and partici- pants suggested specific areas for improvement, including the validation of targets, the design of experiments, how results are statistically ana- lyzed, and the way in which positive and negative results are reported. Many participants supported increasing cross-sector collaboration, strengthening training programs and improving the reproducibility of research with a goal of improving translational efforts. Finally, several participants pointed to the need to merge new tools, technologies, and techniques with current research methods, including animal models, as a way to accelerate therapeutic development for nervous system diseases and disorders.